Deutetrabenazine

Deutetrabenazine: Overview

Deutetrabenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor used for the management of involuntary movement disorders in adults. It provides targeted symptomatic management for chorea associated with Huntington’s disease and tardive dyskinesia. Structurally, it is a deuterated form of tetrabenazine containing carbon-deuterium bonds that slow down liver metabolism, extending the half-life of its active metabolites. This structural feature allows for reduced daily dosing frequency and improved clinical tolerability compared to non-deuterated precursors.

What Is Deutetrabenazine & How Does It Work?

Deutetrabenazine is a hexahydro-dimethoxybenzoquinolizine derivative classified chemically within the tetrahydroisoquinoline family. It serves as an oral, highly selective VMAT2 inhibitor designed to modulate central monoaminergic transmission.

The therapeutic mechanism of deutetrabenazine relies on its major active circulating metabolites, α-dihydrotetrabenazine (α-HTBZ) and β-HTBZ, which reversibly inhibit VMAT2. VMAT2 is the presynaptic protein responsible for loading monoamines such as dopamine, serotonin, norepinephrine, and histamine into synaptic vesicles for exocytotic release into the neuronal synapse. Hyperactive dopaminergic signaling drives involuntary movements like chorea and dyskinesia. By reversibly blocking VMAT2, deutetrabenazine depletes presynaptic dopamine stores and reduces synaptic dopamine release without directly blocking postsynaptic dopamine receptors. The incorporation of non-toxic deuterium strengthens carbon-hydrogen bonds, slowing CYP2D6-mediated clearance and smoothing plasma drug concentrations.

Is Deutetrabenazine FDA Approved?

Deutetrabenazine is FDA approved. The United States Food and Drug Administration granted official approval in April 2017 for the treatment of chorea associated with Huntington’s disease. The FDA subsequently expanded its approved indications to include the treatment of tardive dyskinesia in adult patients.

What Is Deutetrabenazine Used For

• Symptomatic treatment of chorea associated with Huntington’s disease to lessen involuntary movements.
• Management of tardive dyskinesia in adults suffering from persistent, involuntary hyperkinetic movements induced by neuroleptic therapies.
• Target-specific palliative control of hyperdopaminergic motor symptoms in neurodegenerative conditions.

Before Taking Deutetrabenazine: Contraindications & Precautions

Healthcare providers perform careful psychiatric and medical evaluations prior to initiating deutetrabenazine therapy.

Who Should Not Take Deutetrabenazine

• Patients who are actively suicidal or those with untreated or inadequately treated depression.
• Patients with pre-existing hepatic impairment due to elevated drug exposure.
• Individuals taking monoamine oxidase inhibitors (MAOIs) concurrently or within 14 days of stopping MAOI therapy.
• Patients taking reserpine, tetrabenazine, or valbenazine.
• Individuals with a known hypersensitivity to deutetrabenazine or any of its formulation components.

Deutetrabenazine: Pregnancy & Fertility

• Clinical data regarding the developmental safety of deutetrabenazine in pregnant women remains limited.
• Animal studies have shown developmental toxicity only at high doses associated with maternal toxicity.
• Deutetrabenazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Nursing mothers must weigh the benefits of breastfeeding against potential drug exposure risks, as excretion into human milk is unstudied.

Tell Your Doctor Before Taking Deutetrabenazine

• Personal or family history of depression, suicidal ideation, or psychiatric conditions.
• Pre-existing heart conditions, cardiac arrhythmias, long QT syndrome, or uncorrected electrolyte imbalances.
• Concurrent use of strong CYP2D6 inhibitors or drugs known to prolong the QT interval.
• Pre-existing liver dysfunction or severe hepatic disease.

Deutetrabenazine: Dosage & Administration

Dosing of deutetrabenazine must be individualized based on clinical response and tolerability.

Standard Deutetrabenazine Dosing

• For Huntington’s chorea, the starting dose is typically 6 mg once daily, titrated weekly by 6 mg per day based on chorea control and safety.
• For tardive dyskinesia, the starting dose is typically 12 mg daily (6 mg twice daily), titrated weekly as clinically indicated.
• The maximum recommended total daily dose is 48 mg per day (24 mg twice daily or as a single extended-release dose).
• For poor CYP2D6 metabolizers or patients taking strong CYP2D6 inhibitors, the maximum total daily dose should not exceed 36 mg per day.

How Deutetrabenazine Is Administered

• Take oral tablets whole with food to ensure proper systemic bioavailability.
• Do not chew, crush, or break extended-release tablets or film-coated formulations.
• Administer total daily doses of 12 mg or higher in two divided doses per day for immediate-release formulations.

Deutetrabenazine: Clinical Efficacy & Research

Clinical trials demonstrate that deutetrabenazine significantly reduces maximal chorea scores in Huntington’s disease compared to placebo over 12 weeks of therapy. Clinical studies in patients with tardive dyskinesia confirmed statistically significant improvements in involuntary movement scale scores. Research highlights that deuteration provides sustained plasma drug levels, supporting symptom control with lower overall daily doses than non-deuterated tetrabenazine. Deutetrabenazine provides palliative motor management without halting underlying neurodegenerative disease progression.

Deutetrabenazine: Side Effects & Safety Profile

Because deutetrabenazine depletes central monoamines, patients must be observed closely for neurological and psychiatric side effects.

Common Deutetrabenazine Side Effects

• Somnolence, sedation, and fatigue.
• Diarrhea and dry mouth.
• Insomnia and akathisia (restlessness).

Serious Deutetrabenazine Adverse Events

• Emergence or worsening of severe depression, suicidal thoughts, or suicidal behavior.
• Neuroleptic Malignant Syndrome (NMS), presenting with hyperthermia, rigidity, and autonomic instability.
• QTc interval prolongation and serious cardiac arrhythmias.
• Severe parkinsonism or severe akathisia requiring dose reduction.

Managing Deutetrabenazine Side Effects

If severe somnolence or parkinsonism develops, clinicians may reduce the daily dosage. If new or worsening depression or suicidal thoughts occur, the drug should be re-evaluated and potentially discontinued under medical supervision. Patients experiencing high fever, muscle stiffness, or rapid heartbeat should seek emergency care immediately.

Deutetrabenazine: Interactions & What to Avoid

Deutetrabenazine is cleared primarily via hepatic CYP enzymes and alters central monoamine balance.

Deutetrabenazine: Interactions

• Concomitant use with MAOIs is contraindicated due to risks of severe monoaminergic toxicity and hypertensive crisis.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) double active metabolite concentrations, requiring a reduction in maximum recommended dosage.
• Co-administration with QTc-prolonging drugs (e.g., antipsychotics, certain antiarrhythmics) increases the risk of dangerous cardiac arrhythmias.
• Combining with dopamine antagonists or antipsychotics increases risks of parkinsonism, NMS, and severe akathisia.

Deutetrabenazine: Food & Alcohol

• Always take tablets with food, as food intake significantly enhances absorption.
• Avoid alcohol consumption, as alcohol potentiates central nervous system depression and somnolence.

Deutetrabenazine: Missed Dose, Overdose & Storage

Proper adherence and handling prevent fluctuations in symptom control.

Missed Dose of Deutetrabenazine

If a dose is missed, take it with food as soon as remembered unless it is almost time for the next scheduled dose. Do not double doses to make up for a missed dose. If treatment is interrupted for more than 7 days, re-titration may be necessary under medical guidance.

Deutetrabenazine: Overdose & Emergency

Overdosage of VMAT2 inhibitors can lead to severe central nervous system depression, marked extrapyramidal symptoms, severe hypotension, hypothermia, and QTc prolongation. In cases of overdose, seek immediate emergency medical care and monitor cardiac function continuously.

How to Store Deutetrabenazine

Store tablets at controlled room temperature between 20°C and 25°C (68°F to 77°F). Keep the bottle tightly closed to protect from light and moisture, and keep securely out of reach of children.

Deutetrabenazine: Patient Management & Monitoring

Clinicians manage treatment using routine psychiatric and physical monitoring.

Tests Before Starting Deutetrabenazine

• Baseline psychiatric assessment for depression, mood changes, and suicidal ideation.
• Baseline hepatic function testing.
• Baseline electrocardiogram (ECG) in patients with cardiac risk factors or those taking QTc-prolonging drugs.
• CYP2D6 metabolizer testing if clinically indicated.

Monitoring During Deutetrabenazine Treatment

• Ongoing assessment for mood deterioration, emerging depression, or suicidal ideation at every visit.
• Routine evaluation of involuntary movement severity (e.g., AIMS scale for tardive dyskinesia).
• Monitoring for parkinsonian symptoms, akathisia, or excessive sedation.

Deutetrabenazine: Do’s and Don’ts

• Do take every dose with meals to ensure proper drug absorption.
• Do report sudden mood changes, sadness, or suicidal thoughts to your healthcare provider immediately.
• Do not stop taking deutetrabenazine abruptly without consulting your prescribing physician.
• Do not drink alcohol or drive if you experience significant somnolence or dizziness.

Frequently Asked Questions

References

• U.S. FDA – Austedo (deutetrabenazine) prescribing information
• U.S. FDA Drugs@FDA – Deutetrabenazine regulatory history
• DrugBank Database – Deutetrabenazine (DB12161) Detailed Summary

Legal Disclaimer

The information provided in this drug profile is strictly for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider or board-certified psychiatrist before starting, stopping, or altering any medication.